Medicare IVIG payments
Executive Summary
HHS is directed to conduct a study to determine the extent to which intravenous immune globulin could be provided and reimbursed for outpatient use under Medicare as part of the Balanced Budget Act refinements included in the omnibus spending bill. Congress has asked that the department "(A) consider the sites of service that other payors, including Medicare+Choice plans, use for these drugs and biologicals; (B) determine whether covering the delivery of these drugs and biologicals in a Medicare patient's home raises any additional safety and health concerns for the patient; (C) determine whether covering the delivery of these drugs and biologicals in a patient's home can reduce overall spending under the Medicare program; and (D) determine whether changing the site of setting for these services would affect beneficiary access to care." HHS is directed to submit the report to Congress within 18 months of enactment of the bill